Ignite Creation Date:
2024-05-05 @ 4:42 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00294996
Status:
UNKNOWN
Last Update Posted:
2009-03-31
First Post:
2006-02-17
Brief Title:
Trial of Myocet in Metastatic Breast Cancer
Sponsor:
Sopherion Therapeutics
Organization:
Sopherion Therapeutics
Study Overview
Official Title:
A Phase III Randomized Controlled Trial of Myocet Trastuzumab and Paclitaxel Versus Trastuzumab and Paclitaxel for First-Line Therapy of Metastatic Breast Cancer
Status:
UNKNOWN
Status Verified Date:
2009-03
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to examine the safety and effectiveness of the drug combination of Myocet paclitaxel and trastuzumab compared to paclitaxel and trastuzumab without Myocet as first line treatment for patients with metastatic HER2 breast cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None